Publication: Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection.
| dc.contributor.author | Martín-Martín, Clara | |
| dc.contributor.author | Ruiz-Rico, María | |
| dc.contributor.author | Barat, José Manuel | |
| dc.contributor.author | García-Ríos, Estéfani | |
| dc.contributor.author | Pérez-Romero, Pilar | |
| dc.contributor.funder | Instituto de Salud Carlos III | |
| dc.contributor.funder | Agencia Estatal de Investigación (España) | |
| dc.contributor.funder | Generalitat Valenciana (España) | |
| dc.contributor.funder | University of Notre Dame | |
| dc.date.accessioned | 2026-06-30T20:06:36Z | |
| dc.date.available | 2026-06-30T20:06:36Z | |
| dc.date.issued | 2026-03 | |
| dc.description.abstract | Human cytomegalovirus (HCMV) poses serious health risks, particularly for immunocompromised individuals. However, the current FDA-approved anti-HCMV drugs face challenges such as drug resistance and significant side effects, underscoring the need for alternative treatment options. Essential oil components (EOCs), including eugenol, thymol and vanillin, are recognized for their therapeutic potential. This study evaluates their antiviral effects against HCMV in epithelial (ARPE-19) and fibroblast (MRC-5) cell lines. Among the EOCs, vanillin demonstrated the highest efficacy, characterized by low toxicity and a high selectivity index in both cell types. Mechanistic differences were noted between the cell lines. In ARPE-19 cells, eugenol showed virucidal activity, inhibited viral entry and suppressed early gene expression (IE-1). Conversely, in MRC-5 cells, eugenol mainly blocked viral entry and exhibited virucidal effects. Thymol was most effective in ARPE-19 cells, where it completely suppressed IE-1 expression as a result of both inhibition of viral entry and a direct disruptive effect on IE-1 expression. In addition, thymol showed an effect on viral replication. In MRC-5 cells, thymol primarily inhibited viral entry and attachment. Vanillin exhibited dual inhibitory activity in both cell lines, blocking viral attachment and entry. In MRC-5, vanillin also appears to affect intermediate processes. Notably, combining EOCs with ganciclovir resulted in synergistic effects. The eugenol/ganciclovir combination was particularly effective in ARPE-19 cells, while thymol/ganciclovir showed enhanced efficacy in MRC-5 cells. These findings suggest that EOCs have significant potential as adjunct therapies to improve antiviral outcomes and address drug-resistant HCMV strains. | |
| dc.description.peerreviewed | Sí | |
| dc.description.sponsorship | This study was supported by the Spanish Ministry of Science, Innovation and University, Instituto de Salud Carlos III Grant/Award Numbers: PI20CIII-00009 (MPY303/20) and PID2021-128141OB-C21 funded by MCIN/AEI/10.13039/501100011033, by 'ERDF A way of making Europe' and by the Start-up Research Grant University Notre Dame. C.M.-M. is supported by the PFIS Program (FI22CIII/0029), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades. E.G.-R. was supported by the Generalitat Valenciana plan GenT grant no. CIDEIG/2022/028. | |
| dc.format.number | 3 | |
| dc.format.page | 002248 | |
| dc.format.volume | 107 | |
| dc.identifier.citation | Martín-Martín C, Ruiz-Rico M, Barat JM, García-Ríos E, Pérez-Romero P. Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection. J Gen Virol. 2026 Mar;107(3):002248. doi: 10.1099/jgv.0.002248. PMID: 41849209; PMCID: PMC12999277. | |
| dc.identifier.doi | 10.1099/jgv.0.002248 | |
| dc.identifier.journal | Journal of General Virology | |
| dc.identifier.pubmedID | 41849209 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12105/27579 | |
| dc.language.iso | eng | |
| dc.publisher | Microbiology Society | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Proyectos de Investigación en Salud-AESI 2020/PI20CIII%2F00009/ES/Caracterización de la respuesta inmune de anticuerpos en pacientes con trasplante para el diseño de una vacuna/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-128141OB-C21/ES/APLICACION DE MATERIALES FUNCIONALIZADOS CON ACTIVIDAD ANTIVIRICA, ANTIBIOFILM, ANIENZIMATICA Y ANTIMICROBIANA EN LA INDUSTRIA ALIMENTARIA/ | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII//FI22CIII%2F0029/ES// | |
| dc.relation.projectID | info:eu-repo/grantAgreement/Generalitat Valenciana/plan GenT/CIDEIG%2F2022%2F028/ES// | |
| dc.relation.publisherversion | https://doi.org/10.1099/jgv.0.002248 | |
| dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología (CNM) | |
| dc.repisalud.institucion | ISCIII | |
| dc.rights.accessRights | open access | |
| dc.rights.license | Attribution 4.0 International | en |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | Antiviral treatment | |
| dc.subject | Eugenol | |
| dc.subject | Human cytomegalovirus | |
| dc.subject | Thymol | |
| dc.subject | Vanillin | |
| dc.subject | Viral infection and dissemination | |
| dc.subject.mesh | Antiviral Agents | |
| dc.subject.mesh | Benzaldehydes | |
| dc.subject.mesh | Cell Line | |
| dc.subject.mesh | Cytomegalovirus Infections | |
| dc.subject.mesh | Cytomegalovirus | |
| dc.subject.mesh | Epithelial Cells | |
| dc.subject.mesh | Eugenol | |
| dc.subject.mesh | Fibroblasts | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Thymol | |
| dc.subject.mesh | Virus Internalization | |
| dc.subject.mesh | Virus Replication | |
| dc.title | Decoding the antiviral potential of eugenol, thymol and vanillin against human cytomegalovirus infection. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | a1288d49-5ff8-4e1b-ae56-1a46945b94ef | |
| relation.isAuthorOfPublication.latestForDiscovery | a1288d49-5ff8-4e1b-ae56-1a46945b94ef | |
| relation.isFunderOfPublication | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isFunderOfPublication | 54733407-1d78-4c44-bf4c-8c8a7592aa4b | |
| relation.isFunderOfPublication | 842e6617-7822-4501-a927-7e8cedda4aa6 | |
| relation.isFunderOfPublication | ff8a7a14-d84a-487a-bf80-f968c0ac36b2 | |
| relation.isFunderOfPublication.latestForDiscovery | 7d739953-4b68-4675-b5bb-387a9ab74b66 | |
| relation.isPublisherOfPublication | 620794b5-bfea-4aaf-9993-35c681ba12cd | |
| relation.isPublisherOfPublication.latestForDiscovery | 620794b5-bfea-4aaf-9993-35c681ba12cd |


